Company Description
Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States.
The company markets Ampyra (dalfampridine), an oral drug to improve walking in adults with multiple sclerosis; and Inbrija, an inhaled levodopa for intermittent treatment of OFF periods in people with Parkinson’s disease treated with a carbidopa/levodopa regimen.
It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, it has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra.
The company was incorporated in 1995 and is headquartered in Pearl River, New York. On April 1, 2024, Acorda Therapeutics, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of New York.
The plan was later approved as Chapter 11 liquidation on August 7, 2024.
| Country | United States |
| Founded | 1995 |
| IPO Date | Feb 10, 2006 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 102 |
| CEO | Ron Cohen |
Contact Details
Address: 2 Blue Hill Plaza, 3rd Floor Pearl River, New York 10965 | |
| Phone | 914 347 4300 |
| Website | acorda.com |
Stock Details
| Ticker Symbol | ACORQ |
| Exchange | OTCMKTS |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001008848 |
| ISIN Number | US00484M7002 |
| Employer ID | 13-3831168 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Ron Cohen M.D. | Founder, Chief Executive Officer, President and Director |
| Michael A. Gesser M.B.A. | Chief Financial Officer and Treasurer |
| Neil S. Belloff Esq. | General Counsel and Corporate Secretary |
| Denise J. Duca | Executive Vice President of Human Resources |
| Kerry M. Clem | Chief Commercial Officer |
| Sofia Ali | Senior Vice President of Operations and Strategic Planning |
| Susan Way | Senior Vice President of Drug Development and Regulatory Affairs |
| Dr. Wise Young M.D., Ph.D. | Special Scientific Advisor |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 13, 2024 | 15-12G | Securities registration termination |
| Aug 12, 2024 | EFFECT | Notice of Effectiveness |
| Aug 12, 2024 | EFFECT | Notice of Effectiveness |
| Aug 12, 2024 | EFFECT | Notice of Effectiveness |
| Aug 12, 2024 | EFFECT | Notice of Effectiveness |
| Aug 12, 2024 | EFFECT | Notice of Effectiveness |
| Aug 9, 2024 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Aug 9, 2024 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Aug 9, 2024 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Aug 9, 2024 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |